WELTON WASHINGTON: Open Payments
NPI 1841201290 · YPSILANTI, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$489,331 in 588 payments from 10 companies in 2025. Trend: 2023 $272,292 · 2024 $291,257 · 2025 $489,331
Speaker / faculty: $430,700Travel & lodging: $24,425Consulting: $20,785Food & beverage: $13,337Education: $84
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 166 | $124,754 |
| E.R. Squibb & Sons, L.L.C. | 126 | $105,384 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 106 | $95,530 |
| Teva Pharmaceuticals USA, Inc. | 46 | $51,530 |
| Otsuka America Pharmaceutical, Inc. | 41 | $42,239 |
| Alkermes, Inc. | 52 | $42,073 |
| ABBVIE INC. | 35 | $27,502 |
| Janssen Pharmaceuticals, Inc | 12 | $220 |
| Neurocrine BioSciences, Inc. | 3 | $59 |
| Lundbeck LLC | 1 | $39 |
Products named: FANAPT, CAPLYTA, COBENFY, REXULTI, AUSTEDO XR, VRAYLAR, UZEDY, ARISTADA.
Industry payments across MI — which companies pay providers there.
